Loading
institutionsInstitution
University of Wisconsin Carbone Cancer Center
One of the original 1973 NCI comprehensive centres, where 5-fluorouracil was synthesised, reverse transcriptase was discovered and TomoTherapy was invented.
Also called: UWCCCMcArdle Laboratory
Overview
UW Carbone is one of the original NCI comprehensive centres (1973) and grew out of the McArdle Laboratory for Cancer Research, founded in 1940 as the first US university department devoted to cancer research. Charles Heidelberger synthesised 5-fluorouracil at McArdle in 1957; Howard Temin discovered reverse transcriptase here (Nobel Prize 1975); Rock Mackie invented TomoTherapy, the first CT-integrated intensity-modulated radiotherapy system. Paul Sondel's anti-GD2 immunotherapy programme helped establish dinutuximab for neuroblastoma through the Children's Oncology Group, and Douglas McNeel develops DNA vaccines for prostate cancer. The centre is named for Paul Carbone, long-time chair of ECOG.
Location
Madison, WI, US
Type
cancer center · University of Wisconsin-Madison
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#63 · 47 points (0 Newsweek + 15 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University of Wisconsin Carbone Cancer Center, including child institutions. 424 works · 10,177 citations · 68% open access · 13% clinical trials · 3% reviews.
Oncology works per year
742022
942023
962024
1012025
592026
Most works
- Noelle K. LoConte30 works
- Dustin A. Deming29 works
- Reem Karmali28 works
- Deborah M. Stephens25 works
- Vaishalee P. Kenkre24 works
- Lindsey Fitzgerald24 works
- Leo I. Gordon23 works
- Brian Hess23 works
- Tamara K. Moyo23 works
- Priyanka A. Pophali23 works
Most cited
- Radiation oncology (TomoTherapy heritage)
- Paediatric immunotherapy (anti-GD2)
- Prostate cancer vaccines
- Cancer biology (McArdle)
Similar pages
- PersonAlice L. Yu
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PersonJulie R. Park
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- TrialCOG ANBL0032
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
- TechnologyRing-gantry linacs (Halcyon, Ethos)
Shares TomoTherapy and Radixact (helical radiotherapy), MR-guided adaptive radiotherapy, IMRT / IGRT (modern external beam), Prostate cancer.
- TrialANBL17P1
Shares Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric), Cytotoxic chemotherapy.
- InstitutionSidney Kimmel Comprehensive Cancer Center at Jefferson Health
Shares Off-the-shelf cancer vaccines, National Cancer Institute (NIH), Prostate cancer, Colorectal cancer.
- TrialANBL1221
Shares Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric), Cytotoxic chemotherapy.
cancers
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-GD2, chimeric)
Dinutuximab (ch14.18) / dinutuximab beta · Unituxin / Qarziba (EU)